Literature DB >> 7558130

Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis.

C R Brown1, C A Hunter, R G Estes, E Beckmann, J Forman, C David, J S Remington, R McLeod.   

Abstract

Control of resistance to cyst burden following per-oral infection with Toxoplasma gondii has been mapped previously to a region of mouse chromosome 17 of approximately 140 kb. This region is contiguous with and contains the class I gene, Ld. Resistance to development of toxoplasmic encephalitis has also been reported to be controlled by genes in this region of H-2. TNF-alpha, D and L genes, as well as unidentified genes, are also in this region. The work described here was performed to identify definitively the gene(s) in this 140 kb region that confers resistance to cysts and encephalitis. The study demonstrates that relative resistance to T. gondii organisms and cyst burden in brain, and toxoplasmic encephalitis, 30 days following per-oral T. gondii infection is correlated absolutely with the presence of the Ld gene in inbred, recombinant, mutant and C3H.Ld transgenic mice. Mice with the Ld gene had lower cyst burdens and less encephalitis than those without the Ld gene. Specifically, 30 days after infection mice with the Ld gene had minimal perivascular inflammation and meningeal inflammation and very few Toxoplasma cysts or organisms in immunoperoxidase-stained preparations of their brains. Mice without the Ld gene had a similar pattern of inflammation, but in addition they had collections of inflammatory cells in the brain parenchyma. Free tachyzoites were found within these foci of inflammation and cysts were present in these areas as well as in contiguous areas without inflammatory cells. There were CD4+ and CD8+ T lymphocytes in the areas of inflammation and throughout the brain parenchyma. Mice that were resistant to cysts and encephalitis had little detectable brain cytokine mRNA expression, while mice that were susceptible had elevated levels of mRNA for a wide range of cytokines, consistent with their greater amounts of inflammation. The present work definitively demonstrates that a Ld-restricted response decreases the number of organisms and cysts within the brain and thereby limits toxoplasmic encephalitis and levels of interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), IL-6, IL-10, transforming growth factor-beta (TGF-beta), IL-1 alpha, IL1 beta and macrophage inhibiting protein (MIP) mRNA in the brain 30 days after per-oral infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558130      PMCID: PMC1383915     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  H-2 complex-linked resistance in murine toxoplasmosis.

Authors:  T C Jones; P Erb
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

3.  Genetic analysis of the H-2D region using a new intra-D-region recombinant mouse strain.

Authors:  L W Duran; J C Zeller; J K Lundy; A Chang-Miller; C J Krco; C S David; L R Pease
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

4.  Immunohistological study of the anatomic relationship of toxoplasma antigens to the inflammatory response in the brains of mice chronically infected with Toxoplasma gondii.

Authors:  F K Conley; K A Jenkins
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

5.  Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice.

Authors:  Y Suzuki; F K Conley; J S Remington
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

6.  Immune response of mice to ingested Toxoplasma gondii: a model of toxoplasma infection acquired by ingestion.

Authors:  R McLeod; R G Estes; D G Mack; H Cohen
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

7.  Strain-dependent differences in murine susceptibility to toxoplasma.

Authors:  F G Araujo; D M Williams; F C Grumet; J S Remington
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

8.  Immune responses associated with early survival after peroral infection with Toxoplasma gondii.

Authors:  R McLeod; P Eisenhauer; D Mack; C Brown; G Filice; G Spitalny
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

9.  Molecular studies of murine mutant BALB/c-H-2dm2 define a deletion of several class I genes including the entire H-2Ld gene.

Authors:  R J Rubocki; T H Hansen; D R Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  Genetic control of murine resistance to Toxoplasma gondii.

Authors:  D M Williams; F C Grumet; J S Remington
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

View more
  69 in total

Review 1.  The development and biology of bradyzoites of Toxoplasma gondii.

Authors:  L M Weiss; K Kim
Journal:  Front Biosci       Date:  2000-04-01

2.  Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.

Authors:  J P Dubey; L R Ferreira; J Martins; Rima McLeod
Journal:  Parasitology       Date:  2011-11-14       Impact factor: 3.234

3.  Identification of quantitative trait loci controlling acute virulence in Toxoplasma gondii.

Authors:  Chunlei Su; Daniel K Howe; J P Dubey; James W Ajioka; L David Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

4.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

5.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

Review 6.  Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain.

Authors:  Yasuhiro Suzuki; Qila Sa; Marie Gehman; Eri Ochiai
Journal:  Expert Rev Mol Med       Date:  2011-10-04       Impact factor: 5.600

7.  Strains of Toxoplasma gondii used for tachyzoite antigens to stimulate spleen cells of infected mice in vitro affect cytokine responses of the cells in the culture.

Authors:  Laurel Rodgers; Xisheng Wang; Xiangshu Wen; Bradley Dunford; Renee Miller; Yasuhiro Suzuki
Journal:  Parasitol Res       Date:  2005-07-07       Impact factor: 2.289

8.  Organ- and disease-stage-specific regulation of Toxoplasma gondii-specific CD8-T-cell responses by CD4 T cells.

Authors:  Sonja Lütjen; Sabine Soltek; Simona Virna; Martina Deckert; Dirk Schlüter
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

9.  BALB/c mice resistant to Toxoplasma gondii infection proved to be highly susceptible when previously infected with Myocoptes musculinus fur mites.

Authors:  Aurea Welter; José Roberto Mineo; Deise Aparecida de Oliveira Silva; Elaine Vicente Lourenço; Eloísa Amália Vieira Ferro; Maria Cristina Roque-Barreira; Neide Maria da Silva
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

10.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.